P53

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Saturday, May 27, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Saturday, May 27, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Dr. Kieran Murphy Presents Results of Clinical Trial Demonstrating Positive Effect Protecting DNA From Radiation Exposure

Retrieved on: 
Friday, May 26, 2023
Interventional, DNA, CT, Radiation, Clinical trial, Research, Nuclear medicine, CMO, Angiography, Radiology, CAIR, Capsule, Princess Margaret Hospital, X-ray, Journal, DNA repair, McMaster University, Patient, Physician, Risk, UV, Cell nucleus, University Health Network, FRCPC, Cardiology, FDA, Therapy, Health Canada, Mammography, Air pollution, Smoking, Halo, Radiation exposure, P53, Medical imaging, Dietary supplement

Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.

Key Points: 
  • Dr. Kieran Murphy MD, FRCPC, FSIR, Founder, Inventor, and CMO of Cora Therapeutics, announced the efficacy of a proprietary antioxidant complex in safeguarding DNA from radiation exposure during life-saving aortic aneurysm stenting procedures guided by X-ray technology.
  • During these high-intensity image-guided procedures, physicians were administered the antioxidant complex as two capsules, one hour prior to exposure.
  • Dr. Murphy's team has successfully demonstrated the protection of mitochondrial DNA from radiation in these subjects, marking a significant milestone in medical literature.
  • Considering that mitochondrial DNA is inherited maternally and is 13 times more vulnerable to radiation than nuclear DNA, this achievement holds tremendous promise.

Former Cancer Patient Opens 100% Plant-Based Food Cart at Troutdale Station, Oregon

Retrieved on: 
Thursday, January 12, 2023
Restaurant, Bar, Food, Beverage, Health, Retail, Fitness & Nutrition, Brooklyn, Wellington, Reading, Commerce, Prostate cancer, Business, Caldwell, Blood pressure, Southeast Powell Boulevard station, ID, Patient, Radiation, Diet, Cancer, Attitude, Restaurant, Food, Dietary supplement, P53

Today is the grand opening of a new kind of food cart at Troutdale Station – the “P53 Troutdale Station” cart based on the P53 Diet .

Key Points: 
  • Today is the grand opening of a new kind of food cart at Troutdale Station – the “P53 Troutdale Station” cart based on the P53 Diet .
  • By December 2019 he was in remission but in January 2022 the cancer returned and had metastasized to his lungs.
  • Upon today’s launch, Steve and his wife, Tonya, are providing the first 100% plant-based food cart in Troutdale Station.
  • “I’m very excited that Steve and his wife, Tonya, are opening the first food cart using the specialized P53 plan.

Cracking the mystery behind a deadly brain cancer

Retrieved on: 
Wednesday, December 21, 2022
ENTRY, Neuroscience, Cold Spring Harbor Laboratory, Patient, Education, Neoplasm, Laboratory, Brain, Student, Life expectancy, Nobel Prize, Mills, Biomedical Research, Heart, Chromosome, Gene, Mouse, Aggression, Multimedia, Glioblastoma, CSHL, Cancer, BRD8, SPRING, Gene Siskel, Pharmaceutical industry, Vaccine, Medical imaging, P53

COLD SPRING HARBOR, N.Y., Dec. 21, 2022 /PRNewswire/ -- The brain cancer, glioblastoma, is a fierce and formidable opponent.

Key Points: 
  • COLD SPRING HARBOR, N.Y., Dec. 21, 2022 /PRNewswire/ -- The brain cancer, glioblastoma, is a fierce and formidable opponent.
  • But now, Mills and her colleagues have discovered in this deadly cancer a vulnerability, known as BRD8, that may finally lead to new treatment options and better patient outcomes.
  • The CSHL team recently solved a decades-old mystery surrounding glioblastoma's aggressiveness by linking the BRD8 protein to another protein, named P53.
  • A staple in the body's natural cancer defenses , P53 prevents cells from overgrowing and turning into tumors.

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

Retrieved on: 
Thursday, August 5, 2021
Company, Clinical trial, Royal commission, U.S. Securities and Exchange Commission, MDS, European Commission, Coronavirus, Acute myeloid leukemia, P53, Regulation, Breakthrough therapy, AML, Azacitidine, Securities Act of 1933, Therapy, Ovarian cancer, Securities Exchange Act of 1934, Cancer, Regulation Fair Disclosure, Hematological Cancer Research Investment and Education Act, Drug Quality and Security Act, Food and Drug Administration, Neoplasm, Orphan drug, Disclosure, Microdeletion syndrome, Internet service provider, Pharmaceutical industry, Vaccine

The Companys lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.

Key Points: 
  • The Companys lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.
  • APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.
  • The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors.
  • Apreas myeloid malignancy program consists of clinical trials in frontline MDS, AML and post-transplant maintenance therapy in MDS/AML.

Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint

Retrieved on: 
Wednesday, June 16, 2021
Chemical compounds, Organic compounds, Branches of biology, Orphan drugs, Antineoplastic drugs, Lactams, Nucleosides, Triazines, Venetoclax, Azacitidine, P53

The trial met the primary efficacy endpoint of CR, which is based on a Simon 2-stage design.

Key Points: 
  • The trial met the primary efficacy endpoint of CR, which is based on a Simon 2-stage design.
  • As of the data cut, 11 patients remain on study treatment and continue to be followed for safety and efficacy.
  • We are pleased with these results from the combination of eprenetapopt with venetoclax and azacitidine in this very difficult-to-treat TP53 mutant AML population, a patient group with significant unmet medical need, said Eyal Attar, M.D., Chief Medical Officer of Aprea Therapeutics.
  • A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS has been completed and failed to meet the primary statistical endpoint of complete remission.

PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference

Retrieved on: 
Wednesday, June 9, 2021
Branches of biology, Proteins, Tumor suppressor genes, Apoptosis, P53, Programmed cell death, Bert Vogelstein, Mdm2

PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.

Key Points: 
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • p53 mutations are found in approximately half of all cancers.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference

Retrieved on: 
Thursday, June 3, 2021
Branches of biology, Proteins, Cell biology, Biology, Tumor suppressor genes, Apoptosis, P53, Programmed cell death

A replay of the presentation will be available by visiting the Events & Presentations section of the PMV Pharmaceuticals website.

Key Points: 
  • A replay of the presentation will be available by visiting the Events & Presentations section of the PMV Pharmaceuticals website.
  • PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants.
  • The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.

PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights

Retrieved on: 
Friday, May 14, 2021
Branches of biology, Cell biology, Biology, Communication, Forward-looking statement, P53, Pharma

\xe2\x80\x9cEnrollment in our Phase 1/2 trial of PC14586, our first in class p53 Y220C reactivator, is progressing as planned.

Key Points: 
  • \xe2\x80\x9cEnrollment in our Phase 1/2 trial of PC14586, our first in class p53 Y220C reactivator, is progressing as planned.
  • Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus.
  • Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.